Santen Pharmaceutical Co., Ltd.

GPTKB entity

Properties (50)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:acquisition gptkb:Ophthotech_Corporation
Santen_acquired_100%_of_the_shares_of_Eyevance_Pharmaceuticals
Santen_acquired_100%_of_the_shares_of_Oculis_SA
gptkbp:awards received multiple awards for innovation
recognized for excellence in ophthalmology
gptkbp:CEO Akihiro_Santen
gptkbp:clinicalTrials ongoing clinical trials for new ophthalmic drugs
gptkbp:collaborations collaborates with universities for research
gptkbp:communityEngagement engages in community health programs
supports eye health awareness campaigns
gptkbp:financialPerformance increased investment in R&D
reported steady growth in revenue
gptkbp:focus research and development
gptkbp:founded 1890
gptkbp:globalPresence operates in over 30 countries
gptkbp:headquarters gptkb:Osaka,_Japan
https://www.w3.org/2000/01/rdf-schema#label Santen Pharmaceutical Co., Ltd.
gptkbp:industry pharmaceuticals
gptkbp:market gptkb:North_America
gptkb:Asia-Pacific
Europe
gptkbp:numberOfEmployees approximately 2,000
gptkbp:operatesIn gptkb:Asia
gptkb:Japan
gptkb:North_America
Europe
gptkbp:partnerships gptkb:Aerie_Pharmaceuticals
gptkb:Bausch_+_Lomb
Novartis
gptkbp:patentCitation developed proprietary drug delivery systems
holds numerous patents in ophthalmic formulations
gptkbp:products contact lens solutions
surgical products
dry eye treatments
anti-glaucoma medications
ophthalmic_pharmaceuticals
gptkbp:researchFocus retinal diseases
ocular diseases
corneal diseases
inflammatory eye diseases
gptkbp:revenue approximately 200 billion JPY
gptkbp:specializesIn ophthalmology
gptkbp:subsidiary gptkb:Santen_GmbH
gptkb:Santen_Inc.
gptkb:Santen_SA
gptkbp:sustainabilityInitiatives environmental sustainability programs
corporate social responsibility initiatives
gptkbp:vision to be a global leader in ophthalmology
gptkbp:website www.santen.com